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effectiveness and reducing the adverse
effects of antimicrobials and other thera-
peutic agents. Although these applica-
tions are promising, many interesting
questions remain to be answered and
many challenges remain to be over-
come. One important issue is the com-
parability of the results of in vitro and
in vivo studies: the results of in vitro
studies do not necessarily predict the
outcome of in vivo exposure. In addi-
tion, there are growing concerns regard-
ing the potential toxicities of materials
used to fabricate some particles. Addi-
tional studies are needed to improve our
understanding of this important field
now in development.
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Mutant BRAF: A Novel Mediator of
Microenvironmental Escape in
Melanoma?
Keiran S.M. Smalley1,2
The acquisition of mutant BRAF is an important initiating event for melanoma
development, although the process by which transformed melanocytes escape
from keratinocyte control and disseminate to other organs is not well understood.
Boyd et al. (2013) provide evidence that oncogenic BRAF contributes to the
microenvironmental escape of melanocytes through the downregulation of
E-cadherin expression via the transcriptional suppressor Tbx3.
Journal of Investigative Dermatology (2013) 133, 1135–1137. doi:10.1038/jid.2012.474
The earliest stages of melanoma devel-
opment, in which transformed melano-
cytes escape the constraints of the local
microenvironment and disseminate to
lymphatic vessels and distant organs,
are still being elucidated. Under normal
physiological conditions, melanocytes
sit at the basal layer of the epidermis
where they interact closely with sur-
rounding keratinocytes at a ratio of
about 1:5. Under these circumstances,
the two cell types exhibit a close rela-
tionship, with melanin pigment (in the
form of melanosomes) being actively
transported from melanocytes into sur-
rounding keratinocytes. The transfer of
melanin to keratinocytes (aka the tann-
ing response) is critical in providing
photoprotection to skin and serves to
limit the harmful DNA-damaging activ-
ity of solar UV radiation (Tran et al.,
2008). The process of melanin synthesis
and melanosome transport is initiated
by signals that emanate from the
keratinocytes after the UV-mediated
initiation of p53-mediated gene
transcription (Tran et al., 2008). This,
in turn, leads to the release of a-
melanocyte-stimulating hormone from
the keratinocytes and the stimulation of
melanocortin receptor 1 signaling and
melanogenesis in nearby melanocytes.
In addition to these events, keratino-
cytes also control many other aspects
of melanocyte behavior, including
growth, motility, and differentiation
(Haass et al., 2005). This regulation is
achieved through a finely balanced
signaling network involving direct cell–
cell adhesion between melanocytes and
keratinocytes, as well as the release of
paracrine growth factors. One of the key
mediators of melanocyte/keratinocyte
interaction is E-cadherin, a calcium-
dependent glycoprotein that has
important roles in maintaining the cell
architecture in epithelial tissues (Haass
et al., 2005). Loss of E-cadherin expres-
sion is an important step in the majority
of epithelial cancers, and it is a pre-
requisite for dissemination of invasive
cells from the initial tumor mass (Kalluri
and Weinberg, 2009). Typically, loss of
E-cadherin expression is part of a larger
dynamic transcriptional program that is
frequently observed in cancer cells, called
the epithelial-to-mesenchymal transi-
tion (EMT). Other features of the EMT
include the adoption of a mesen-
chymal phenotype, increased extracel-
lular matrix deposition and resistance to
apoptosis (Kalluri and Weinberg, 2009).
Under normal conditions, melanocytes
express high levels of E-cadherin (despite
being derived from the neural crest) with
homotypic E-cadherin-based adhesion
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between melanocytes and keratino-
cytes, constituting an important homeo-
static mechanism in skin. Irrespective of
the initiating oncogene, melanoma
development is usually associated with
decreased E-cadherin expression and an
escape from the control of local keratino-
cytes (Hsu et al., 2000; Haass et al., 2005).
Often, the suppression of E-cadherin
expression is part of a ‘‘cadherin switch’’
that results in a reciprocal increase in the
expression of N-cadherin (Haass et al.,
2005). This increased expression of
N-cadherin contributes to the process of
transformation by allowing melanoma
cells to switch binding partners and to
interact instead with fibroblasts and endo-
thelial cells, as well as through direct
signaling effects that increase melanoma
survival and invasion (Haass et al., 2005).
The importance of E-cadherin downregu-
lation in the development of melanocytic
tumors is illustrated by the observation that
a reintroduction of E-cadherin brings even
aggressive melanoma cells back under
keratinocyte control (Hsu et al., 2000).
Despite many years of research into
the role of E-cadherin downregulation in
melanoma development, the mechanisms
by which transformed melanocytes down-
regulate E-cadherin expression and escape
from the local environment are still poorly
understood.
Melanoma is known to be a diverse
group of tumors whose initiation and
progression is mediated by distinct
oncogenes. By far the most prevalent is
BRAF, which is known to be mutated in
B50% of all cutaneous melanomas
(Smalley, 2010). Although the mecha-
nisms by which mutant BRAF mediates
oncogenic transformation of melano-
cytes have been extensively characteri-
zed, relatively little is known about its
potential role in microenvironmental
escape (Smalley, 2010). The study by
Boyd et al. (2013), published in this
issue of the Journal of Investigative
Dermatology, provides the first evi-
dence that links oncogenic BRAF to
decreased E-cadherin expression. Using
genome-wide transcriptome analysis,
the authors demonstrated that introduc-
tion of the BRAF V600E mutation
induced an ‘‘EMT-like’’ gene signature
in human melanocytes. One of the
major hits identified from the screen
was E-cadherin, whose expression was
found to be suppressed by BRAF at both
the messenger RNA and protein levels.
The BRAF dependency of these effects
was demonstrated through small hair-
pin RNA studies and the ability of the
BRAF inhibitor vemurafenib to par-
tially reverse this, leading to increased
E-cadherin expression. In epithelial
cells, the EMT process is subject to com-
plex regulation by a network of trans-
cription factors such as SLUG, ZEB,
Goosecoid, FOXC2, SNAIL, and
TWIST, whose expression is controlled
partly by growth factors, including trans-
forming growth factor-b, platelet-
derived growth factor, epithelial
growth factor, and hepatocyte growth
factor (HGF) (Kalluri and Weinberg,
2009). Of these, HGF is implicated in
the induction of an EMT-like state in
human melanocytes, an effect mediated
through the increased expression of
SNAIL and SLUG, as well as signaling
through the PI3K/AKT and mitogen-acti-
vated protein kinase (MAPK) signaling
pathways (Haass et al., 2005). Despite
increased SNAIL expression being asso-
ciated with decreased E-cadherin
expression in melanoma cells, Boyd
et al. (2013) did not observe any BRAF-
mediated changes in the expression of
known EMT-associated E-cadherin regula-
tors such as Slug, ZEB, TWIST, EZH2, or
TCF3. Instead, the introduction of mutant
BRAF increased the expression and pro-
moter activity of the transcriptional repres-
sor Tbx3. Tbx3 is a T-box family member
of development-associated transcription
factors implicated in the regulation of
cell proliferation, cell fate, and cell iden-
tity (Rodriguez et al., 2008; Peres et al.,
2010). Overexpression of Tbx3 has been
reported in many cancers, including
melanoma, where it suppresses entry
into senescence through the repression
of the cell cycle inhibitors p14ARF and
p21CIP1 (Peres et al., 2010). Increased Tbx3
expression has been shown to downregu-
late E-cadherin expression in melanoma
cells through direct binding to the initiation
region of its promoter (Rodriguez et al.,
2008). Boyd et al. (2013) confirmed the
link between Tbx3 and E-cadherin
expression and further demonstrated that
knockdown of either BRAF or Tbx3
inhibited invasion by melanoma cells.
Cell migration and invasion is a com-
plex multistep process requiring the
detachment of cells from the matrix,
cytoskeletal reorganization, reattachment,
contraction, and matrix degradation. In
melanoma, oncogenic BRAF is impli-
cated in many of the key processes
required for motility and invasion. Recent
work has shown mutant BRAF to regulate
directly the contractile ability of mela-
noma cells through the suppression of
phosphodiesterase 5A, in turn leading to
increased cGMP accumulation and the
release of cytosolic calcium (Fedorenko
et al., 2011). At the same time, constitu-
tive MAPK signaling directly contributes
to remodeling of the actin cytoskeleton
through the expression of RND3, a medi-
ator in the cross talk between MAPK/ERK
kinase signaling and the Rho/Rock/LIM
kinase/Cofilin pathway (Fedorenko et al.,
2011). Taken together, it is likely that the
reduced melanoma cell invasion obser-
ved by Boyd et al. (2013) following
knockdown of either BRAF or Tbx3 is
the result of the inhibition of the motile/
invasive process at multiple levels. The
link between BRAF mutation status and
Tbx3 expression observed by Boyd et al.
(2013) was also of clinical relevance,
with a clear association being noted bet-
ween BRAF mutational status and Tbx3
expression in human melanoma speci-
mens. Interestingly, little correlation was
seen between either BRAF mutational
status or Tbx3 expression and E-cadherin
Clinical Implications
 Under normal conditions, the behavior of melanocytes is partly regulated
through E-cadherin-mediated interactions with surrounding keratinocytes.
 The acquisition of BRAF mutations downregulates the expression of
E-cadherin in melanocytes through the transcriptional repressor Tbx3,
increasing their invasive capacity.
 Inhibition of BRAF signaling through either small hairpin RNA knockdown
or BRAF inhibitor treatment can partially restore E-cadherin expression.
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levels, suggesting that most melanomas
lost E-cadherin expression and that multi-
ple paths to E-cadherin deregulation exist.
We still do not fully understand all of
the molecular steps required for onco-
genic BRAF to transform melanocytes
fully. Although the introduction of BRAF
V600E into primary human melanocytes
in vitro is associated with an initial burst
of replication, these effects are short-lived
and the cells eventually show signs of
oncogene-induced senescence. A number
of prior studies have suggested that Tbx3
(and the closely related Tbx2) promotes
oncogenesis, partly through the suppres-
sion of senescence. Despite this, and the
possibility that Tbx3 may limit the senes-
cence response in melanocytes, Boyd
et al. (2013) observed oncogenic BRAF
to induce senescence even when Tbx3
expression was increased. These results
add further weight to the emerging idea
that activity in multiple signaling path-
ways may be required to fully drive
melanocyte transformation. Although
Boyd et al. (2013) suggested a role for
p16INK4A in this process, other recent
studies have implicated increased PI3K/
AKT signaling, arising through either
PTEN loss or increased AKT3 expression,
in the escape of melanocytes from BRAF-
mediated senescence (Vredeveld et al.,
2012). It is further likely that the PI3K/AKT
signaling required for the escape from
BRAF-mediated senescence may also
enhance the EMT-like response of mela-
noma cells, leading to further potentiation
of environmental escape (Kalluri and
Weinberg, 2009). Insights into the poten-
tial cooperation between BRAF and the
PI3K/AKT signaling pathways in driving
the EMT-like response of melanoma cells
are likely to prove useful in our under-
standing of the earliest stages of
melanoma development.
The identification of mutant BRAF as a
bona fide therapeutic target in 50% of
melanoma patients and the subsequent
clinical development of small-molecule
BRAF inhibitors may revolutionize the
treatment of disseminated melanoma
(Fedorenko et al., 2011). The findings of
Boyd et al. (2013), as well as of others,
showing that BRAF inhibition reverses
partially the EMT-like state of mela-
noma, could represent a potential mecha-
nism through which BRAF inhibitors such
as vemurafenib and dabrafenib exert their
effects. It is also intriguing that Tbx3,
whose knockdown has multiple effects
on melanoma cells, including the reduc-
tion of anchorage-independent growth
and the abrogation of xenograft forma-
tion in immunocompromised mice, is
suppressed by BRAF inhibitors (Peres
et al., 2010). We are only now begin-
ning to understand how the acquisition of
driver mutations, such as mutant BRAF,
serve to rewire the signaling of melano-
cytes and drive them toward oncogenic
transformation. These insights, linking
mutant BRAF to E-cadherin and Tbx3,
provide important clues about how mela-
noma may be managed therapeutically.
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MicroRNAs as an Emerging Target
for Melanoma Therapy
Byungwoo Ryu1, Soonyean Hwang1 and Rhoda M. Alani1
Despite the growing focus on microRNAs (miRNAs) as novel diagnostic tools and
therapeutic targets in cancer, global characterization of miRNA expression patterns
and their specific targets in melanoma has lagged. In this issue, Reuland et al. (2013)
identify miR-26a as being specifically downregulated in human melanoma cells.
They further establish Silencer of Death Domains as a novel target for miR-26a,
which functionally mediates melanoma cell death. These findings suggest that
miR-26a may serve as a promising novel therapy for subsets of melanoma.
Journal of Investigative Dermatology (2013) 133, 1137–1139. doi:10.1038/jid.2012.505
MicroRNAs (miRNAs) are small non-
coding RNAs that regulate gene expres-
sion at the posttranscriptional level.
Precursor miRNAs are initially tran-
scribed in the nucleus and subsequently
cleaved by RNAse III into mature miR-
NAs. Once in the cytoplasm, these
molecules form an miRNA-induced
silencing complex that binds to the 30
untranslated regions of target transcripts.
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